510(k) · Cleared
ClearedDimension N-Acetylprocainamide (Napa) Flex Reagent Cartridge Method, Model DF111
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Dade Behring, Inc. · LAN Enzyme Immunoassay, N-Acetylprocainamide
Cleared on Oct 31, 2003 as substantially equivalent to K833378 (E.I. Dupont DE Nemours & Co., Inc., 1983) after a 72-day review. Its family tree reaches back 1 generation to 1983. 1 later device descends from it.
- Decided
- Oct 31, 2003
- Review
- 72 days
- Class
- Class II
- Product code
- LAN
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 1 generation to K833378 (1983). 1 later device descends from it, 1 citing it directly.
- Root · 1 generation backK833378 N-Acetylprocainamide Aca-AnalyticalE.I. Dupont DE Nemours & Co., Inc. · 1983
- This deviceK032564 Dimension N-Acetylprocainamide (Napa) Flex Reagent Cartridge Method…Dade Behring, Inc. · 2003
- Descendant · cites it directly · 0 of its ownK062024 Dimension Vista Digitoxin, Digoxin, Gentamicin…Dade Behring, Inc. · 2006 · Recalled
Most influential descendants
Showing 1 of 1 · See all- K062024Dimension Vista Digitoxin, Digoxin, Gentamicin, N-Acetylprocainamide, Phenytoin…Dade Behring, Inc. · 2006 · cites it directly0descendants
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −1 | K833378 | N-Acetylprocainamide Aca-Analytical | E.I. Dupont DE Nemours & Co., Inc. | 1983 | — |
| 0 (this device) | K032564 | Dimension N-Acetylprocainamide (Napa) Flex Reagent Cartridge Method, Model DF111 | Dade Behring, Inc. | 2003 | — |
| +1 | K062024 | Dimension Vista Digitoxin, Digoxin, Gentamicin, N-Acetylprocainamide… | Dade Behring, Inc. | 2006 | 4 |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2006 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in LAN? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
- Candidate predicates for a device like this, rankedin the report
- Recall history across each candidate’s familyin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K833378 | N-Acetylprocainamide Aca-AnalyticalSummary page 1…ication Name: N-acetylprocainamide test system (2 1CFRg 862.3320; 9 1LAR) Predicate Device: Dade Behring aca8 NAPA analytical test pack (K833378) Device Description: The Dade Behring Dimension@ N-acetylprocainamide (NAPA) Flex@ reagent cartridge method is an in vitro diag… | 1983 |
What descends from it? (1)
1 later device cites it directly; ranked here by how many devices descend from each in turn.
| Number | Device | Decided | Descendants |
|---|---|---|---|
| K062024 | Dimension Vista Digitoxin, Digoxin, Gentamicin, N-Acetylprocainamide, Phenytoin… | 2006 | 0 |
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- Its one ancestor has no recall.
- Of its descendants, K062024 (Dade Behring, Inc., 2006) has gone furthest, with 0 descendants of its own.
How does its category compare?
All LAN devicesLAN Enzyme Immunoassay, N-Acetylprocainamide: FDA decisions, review times, recalls and adverse event reports over 20 years.
FDA decisions per year · LAN
FDA has decided no LAN device since 2007.
Median 510(k) review, days · LAN
Too few LAN 510(k)s in any year since 2007 to give a median.
Recalls per year · LAN
1in 2010
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · LAN
No MAUDE report names LAN since 2007.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 0 | 0 |
| 2008 | 0 | — | 0 | 0 |
| 2009 | 0 | — | 0 | 0 |
| 2010 | 0 | — | 1 | 0 |
| 2011 | 0 | — | 0 | 0 |
| 2012 | 0 | — | 0 | 0 |
| 2013 | 0 | — | 0 | 0 |
| 2014 | 0 | — | 0 | 0 |
| 2015 | 0 | — | 0 | 0 |
| 2016 | 0 | — | 0 | 0 |
| 2017 | 0 | — | 0 | 0 |
| 2018 | 0 | — | 0 | 0 |
| 2019 | 0 | — | 0 | 0 |
| 2020 | 0 | — | 0 | 0 |
| 2021 | 0 | — | 0 | 0 |
| 2022 | 0 | — | 0 | 0 |
| 2023 | 0 | — | 0 | 0 |
| 2024 | 0 | — | 0 | 0 |
| 2025 | 0 | — | 0 | 0 |
| 2026 | 0 | — | 0 | — |
What is it indicated for?
The Dade Behring Dimension0 N-acetylprocainamide (NAPA) Flex@ reagent cartridge method is used to measure N-acetylprocainamide in serum or plasma. Measurements may be used in therapeutic drug monitoring to maintain adequate procainamide therapy.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K032564 · printed Nov 5, 2026
Cite this page
510(k) Report. “K032564: Dimension N-Acetylprocainamide (Napa) Flex Reagent Cartridge Method, Model DF111.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K032564
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026